Priscillia Tosti

Colorectal cancer, Collagen receptor DDR1, Metastases

Serge Roche	grad student	2014	Montpellier 1
(Le Nilotinib inhibe les propriétés invasives et métastasantes des cellules de cancer colorectal en ciblant le récepteur à activité tyrosine kinase DDR1)

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Jeitany M, Leroy C, Tosti P, et al. (2018) Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. Embo Molecular Medicine
Tosti P, Leroy C, Simon V, et al. (2013) Abstract 2085: The antileukemic drug nilotinib inhibits the invasive activity and the metastatic potential of colorectal cancer cells by targeting the receptor tyrosine kinase DDR1. Cancer Research. 73: 2085-2085
Leroy C, Tosti P, Simon V, et al. (2012) Abstract 855: The antileukemia drug nilotinib inhibits invasion and metastasis of colorectal cancer cells by targeting the receptor tyrosine kinase DDR1 Cancer Research. 72: 855-855